Deregulation of the Rb/E2F tumor suppressor complex and aberrantion of Sonic hedgehog (Shh) signaling are documented across the spectrum of human malignancies. Exaggerated de novo lipid synthesis is also found in certain highly proliferative, aggressive tumors. Here, we show that in Shh-driven medulloblastomas, Rb is inactivated and E2F1 is upregulated, promoting lipogenesis. Extensive lipid accumulation and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those tumors. In primary cerebellar granule neuron precursors (CGNPs), proposed Shh-associated medulloblastoma cellsof-origin, Shh signaling triggers E2F1 and FASN expression, whereas suppressing fatty acid oxidation (FAO), in a smoothened-dependent manner. In the developing cerebellum, E2F1 and FASN co-localize in proliferating CGNPs. in vivo and in vitro, E2F1 is required for FASN expression and CGNP proliferation, and E2F1 knockdown impairs Shhmediated FAO inhibition. Pharmacological blockade of Rb inactivation and/or lipogenesis inhibits CGNP proliferation, drives medulloblastoma cell death and extends survival of medulloblastoma-bearing animals In vivo. These findings identify a novel mechanism through which Shh signaling links cell cycle progression to lipid synthesis, through E2F1-dependent regulation of lipogenic enzymes. These findings pertinent to the etiology of tumor metabolism also underscore the key role of the Shh-E2F1-FASN axis in regulating de novo lipid synthesis in cancers, and as such its value as a global therapeutic target in hedgehogdependent and/or Rb-inactivated tumors.
Introduction
The Hedgehog (Hh) family of mitogens/morphogens has a pleiotropic role in cell fate determination, organ patterning and expansion of progenitor cell populations (Wechsler-Reya and Scott, 2001 ). Members of the Hh family in mammals include Indian, Desert and Sonic hedgehog (Shh). In development, loss of Hh signaling results in severe abnormalities in mice and humans (Chiang et al., 1996) . Conversely, unrestrained Hh pathway activation is implicated in a variety of tumors, many of which can be traced to Hh-dependent progenitors (Beachy et al., 2004; Eberhart, 2008; Teglund and Toftgard, 2010) . Tumors associated with Hh aberrations comprise cancers of the skin, pancreas, lung and the brain cancer medulloblastoma (Wetmore, 2003; Teglund and Toftgard, 2010) , the most common solid malignant pediatric tumor, and a leading cause of cancer deaths in children. Medulloblastoma arises in the cerebellum as a result of aberrant activity of developmentally critical signaling pathways, including those activated by wnt, Notch and Shh. Of note, Shh mitogenic signaling is required for normal cerebellum development (Dahmane and Ruiz-i-Altaba, 1999; Wechsler-Reya and Scott, 1999) , which is marked by a brief period of rapid proliferation of cerebellar granule neuron precursor (CGNP) cells, proposed to be cells of origin for certain genetically defined classes of medulloblastoma (Eberhart, 2008) .
Secreted Hh proteins trigger downstream signaling through interactions with the tumor suppressor patched (Ptc), a trans-membrane protein localized to lipid rafts (Karpen et al., 2001) whose loss or inactivation is documented in many Hh-dependent human tumors. Indeed, loss of Ptc was first identified in Gorlin's syndrome that predisposes patients to basal cell carcinoma and medulloblastoma (Hahn et al., 1996; Johnson et al., 1996) . In the absence of Shh binding, Ptc inhibits the evolutionarily conserved pathway activated by another transmembrane protein, smoothened (Smo; Ho and Scott, 2002) . Shh interaction with Ptc leads to dis-inhibition of Smo signaling and consequent activation of Smo target genes following translocation from the cytoplasm to the nucleus of Gli transcription factors. Mammals possess three Gli family members, which have activator and repressor functions and are orthologous to Drosophila cubitus interruptus (Hepker et al., 1997) . Gli1 and Gli2 primarily activate transcription in response to activated Smo signaling; in contrast, Gli3 serves to antagonize Shh signaling. In addition to Gli1 and Gli2, other targets of Shh mitogenic signaling include the oncogenic transcriptional regulators N-myc and YAP1, the microRNA miR17/92 and members of the insulin signaling pathway such as IRS1, as well as Ptc itself, presumably as a negative feedback mechanism counteracting excessive Shh signaling (Platt et al., 1997; Kenney et al., 2003; Oliver et al., 2003; Parathath et al., 2008; Fernandez et al., 2009; Northcott et al., 2009; Uziel et al., 2009) .
Notably, many diseases of cholesterol processing involve proteins that resemble Shh pathway components (that is, Neiman-Pick syndrome (Incardona and Eaton, 2000) ) or cause phenotypes reminiscent of Hh pathway malfunction (that is, Smith-Lemli-Opitz syndrome (Kolf-Clauw et al., 1996) ). Shh protein itself is modified by cholesterol and palmitoylation, and it has been reported that cholesterol has downstream roles in Shh signaling (Corcoran and Scott, 2006) . Nonetheless, negative effects of Shh on lipid biosynthesis have also been reported, underscoring the complexity of Shh signaling in the lipid regulatory process (Suh et al., 2006) . In vivo, an understanding of mechanisms through which Shh controls the metabolic machinery remains elusive and whether mitogenic Shh signaling alters lipogenic metabolic patterns to create a permissive environment for proliferation and tumor development is unknown. Nevertheless, many tumors exhibit exaggerated lipogenesis, a process that could fuel tumor growth through providing anabolic growth conditions and critical biomass accumulation, such as cell membrane components and other associated lipid molecules, including lipid rafts which themselves are essential for Shh signal transduction. (Karpen et al., 2001; Menendez, 2009) .
Here, we demonstrate that Shh signaling is directly coupled to lipogenesis in Shh-dependent medulloblastomas and in proliferating CGNPs. We show that Shh promotes de novo fatty acid synthesis (FAS) concomitant with suppressing fatty acid oxidation (FAO) or 'fat burning'. Shh-regulated lipogenesis requires inactivation of the Rb/E2F1 tumor suppressor complex leading to the upregulation of fatty acid synthase (FASN), a key lipogenic enzyme overexpressed in many aggressive tumors (Menendez, 2009) . Down-modulating E2F1 activity and/or E2F1-regulated lipid synthesis has profound negative effects on Shh-associated proliferation and medulloblastoma cell survival. These results provide insights into the etiology of cancer-associated metabolic patterns, demonstrate the functional link coupling the Rb-E2F1 tumor suppressor complex to the lipogenic/lipolytic balance, and underscore the role of Shh signaling in regulating the E2F1-FASN axis in vivo. Findings of this study could have broad implications in cancer, given that unrestrained Hh signaling and Rb pathway deregulation are widespread across the spectrum of human malignancies. These results will influence current treatment paradigms through exploring viable metabolic-based therapeutic modalities targeting E2F-regulated lipogenesis alone or in combination with modulators of E2F1 activity, particularly in contexts where Rb is inactivated or in Hh-associated tumors.
Results
Exaggerated lipogenesis in Shh-induced medulloblastomas coincides with Rb inactivation and E2F1 induction NeuroD2-SmoA1 mice are transgenic for an activated mutant Smo allele driven by the NeuroD2 promoter (Hatton et al., 2008) . Approximately 60% of these mice develop medulloblastomas by 6 months of age. Exaggerated lipogenesis, indicative of active de novo lipid synthesis is detected in these tumors. Indeed, the tumors-unlike adjacent non-tumor cerebellar tissuecan be identified by a striking accumulation of large lipid droplets (as indicated by Oil Red O stain used to mark neutral lipids, Figure 1a ). Of note, recent studies from our lab have linked the expression of E2F1 or the inactivation of its negative regulator Rb to inhibition of glucose oxidation, a process typically associated with increased lipogenesis especially in pathological contexts such as obesity and diabetes (Hsieh et al., 2008) . Indeed, NeuroD2-SmoA1 medulloblastomas have high levels of phosphorylated (inactivated) Rb, accompanied by increased levels of E2F1 (Figures 1b and c) . E2F1 expression also correlates with levels of the lipogenic enzyme FASN (Figures 1b and c) , as well as the proliferation marker phosphorylated histone H3. These results suggest that under Shh pathway deregulation, aberrant E2F1 expression can be associated with priming the lipogenic machinery, potentially favoring a lipogenic phenotype in this Shh-driven cancer.
Shh increases levels of E2F1 and FAS in CGNPs
Above, we showed an association between Shh signaling and the Rb/E2F1-FASN axis in spontaneous medulloblastomas, proposed to arise from CGNPs (Eberhart, 2008) , whose proliferation during perinatal development requires mitogenic signaling by Shh. To a large extent, primary cultures of CGNPs recapitulate the mitogenic signaling seen in the NeuroD2-SmoA1 medulloblastomas. As shown in Figure 2a , pRb is phosphorylated in Shh-treated wild-type CGNPs (Figure 2a ; Kenney and Rowitch, 2000) . This phosphorylation was blocked by acute treatment with forskolin, which activates protein kinase A, a Shh pathway antagonist (Hammerschmidt et al., 1996) , indicating that Rb phosphorylation occurs as a result of Shh pathway activation in proliferationcompetent CGNPs.
Consistent with cdk-mediated Rb inactivation lying downstream of Shh signaling, increased levels of cdk2, cdk4 and cdk6 protein were detected in Shh-treated CGNPs, and correlated with increased activation of cdk2 as determined by in vitro immunoprecipitation kinase assays (Figure 2b and c) . These results predict that E2F proteins are activated in Shh-treated proliferating CGNPs, and indeed, increased levels of E2F1 (and E2F2, data not shown) protein and mRNA are seen in the presence of Shh (Figures 2d and e) . Of note, levels of E2F1 mRNA increased over time, suggesting that in vitro, Shh strongly promotes E2F protein activity, as E2F1 positively regulates its own expression (Johnson et al., 1994) . E2F1 induction also corresponds to Shh signaling pathway activation as determined by Gli1 expression in CGNPs treated with exogenous Shh (Figure 2f ). Importantly, Shh-treatment of CGNPs causes induction of the lipogenic enzyme acetyl CoA carboxylase (ACC) as well as FASN, consistent with the observations in NeuroD2-SmoA1 medulloblastomas. Co-treatment with the Smo inhibitor cyclopamine (Berman et al., 2002) blocked Shh-mediated induction of FASN, ACC and E2F1. We next examined the levels of the sterol regulatory element binding protein 1 (SREBP1), a master regulator of FASN transcription and whose activity and expression could be regulated in response to mitogens and nutrient sensors (Menendez and Lupu, 2007) . As shown in Figure 2h , Shh stimulates levels of SREBP1 protein expression, both in the precursor and cleaved (active) form as well as its mRNA expression (data not shown). Together, our findings thus far indicate that Shh signaling in proliferating primary neural precursors and medulloblastoma cells is associated with induction of E2F1 and the ACC-FAS lipogenic axis, an effect that can be reversed by down-modulating Shh signaling.
Shh suppresses mitochondrial b-oxidation in CGNPs FAO is intimately coupled to FAS and the lipogenic process. To that extent, FAO and FAS are inversely linked: activation of one typically adversely influences the other (Dowell et al., 2005) . A critical regulatory component of this balance lies in the activity of the aforementioned key enzyme ACC that modifies acetylCoA into malonyl-CoA, which is a potent inhibitor of mitochondrial b-oxidation and is also a substrate for FASN (Figure 3a) . We asked whether Shh-triggered FASN expression corresponds to reduce FAO capacities. First, we examined the expression of key FAO regulators, including ACC, as well as ACOX1 and MCAD, two enzymes whose expression reflects (Figure 3b) . Notably, treatment of CGNPs with C75, a FASN inhibitor (Thupari et al., 2002) , resulted in powerful suppression of FASN expression and corresponding induction of ACOX1 and MCAD ( Figure 3b ). This is consistent with reported effects of C75 on promoting FAO in cultured cortical neurons and other cells (Loftus et al., 2000; Kim et al., 2004; Thupari et al., 2004) . Next, we determined whether Shh functionally inhibits the rates of mitochondrial FAO in CGNPs. Palmitate oxidation was measured radiometrically to determine FAO rates as described (Djouadi et al., 2003) . Indeed, Shh has a dramatic effect, significantly reducing FAO in primary CGNPs, compared with vehicle-treated CGNPs. Importantly, inhibiting Shh signaling with cyclopamine was sufficient to counteract the effect of Shh, restoring FAO rates almost to basal vehicle-control treated levels ( Figure 3c ); cyclopamine alone had no effect on expression of FAS and FAO enzymes ( 
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Figure 2 Shh signaling inactivates Rb and induces lipogenesis markers in primary CGNP cultures. (a) CGNP cultures were prepared from PN 4/5 mice and incubated with vehicle (Veh), Shh (3 mg/ml) and/or forskolin (10 mM) for up to 48 h. Protein lysates were prepared and assayed for Rb phosphorylation as determined by upward mobility shift of the total protein. 50 mg protein/lane were loaded. (b) CGNP cultures were treated with vehicle or Shh (3 mg/ml) for 24 h, then analyzed for levels of cdk 2, cdk 4 and cdk 6. (c) CGNP cultures prepared and treated as described above were analyzed for cdk2 kinase activity using immune complex kinase assays. In brief, 200 mg protein lysate were incubated with protein A sepharose beads bound with antibodies against cdk2 or p48 MAPK, whose levels of activity are known not to be altered by Shh signaling. Beads were collected by centrifugation, washed and incubated with substrate (cdk 2, histone H1; p48 MAPK, myelin basic protein) in the presence of gP Hedgehog signals via E2F1 to promote lipogenesis B Bhatia et al the mitochondrial b-oxidation machinery, in a manner reversible by an established inhibitor of Shh-mediated proliferation. Evidently, Shh signaling modulates the lipolytic/lipogenic balance in CGNPs, a process that is seemingly coupled to its mitogenic effects, likely through the activation of E2F1.
E2F1 is necessary for Shh-mediated proliferation and FAO suppression in CGNPs Next, we took advantage of E2F1-deficient mice to address the requirement and/or contribution of E2F1 to Shh-regulated induction of FASN and the control of FAO in proliferating CGNPs. We analyzed protein lysates and histological sections from neonatal wild-type and age-matched E2F1 À/À mouse cerebella to characterize the relationship between E2F1 and FAS. A striking reduction of FASN protein, as well as the proliferation marker cyclin D2 is found in E2F1-deficient cerebella (Figures 4a and b) , compared with wild-type counterparts. We also observed a reduction in SREBP1 levels in E2F1-deficient cerebella, consistent with the expression data in CGNPs. Nonetheless, levels of the cleaved enzyme were not significantly altered and it remains unclear at this stage whether a change in overall SREBP1 levels could explain the striking abrogation of FASN expression seen with E2F1 loss. Significantly, at post-natal day 7, the peak of CGNP proliferation in vivo, E2F1 and FASN localized to the external granule layer (EGL) in wild-type pups, where CGNP proliferation takes place (Figure 4b , left and center panels). In contrast, the PN7 E2F1-null EGL has nearly undetectable FASN protein. These cerebella also exhibited strikingly reduced proliferation (phosphohistone H3 staining Figure 4b , center panels, 4C). As shown by hematoxylin and eosin staining (Figure 4b ), the PN7 E2F1 À/À EGL was reduced in thickness compared with that of age-matched wild-type controls. Reduced EGL thickness and diminished CGNP proliferation in the absence of E2F1 could underlie the observation that the E2F1-null adult cerebellum is hypocellular (Cooper-Kuhn et al., 2002) .
To confirm that reduced proliferation and diminished FASN levels in neonatal E2F1 À/À CGNPs was due to loss of E2F1, specifically in these cells and not a result of an earlier developmental defect, Shh-treated wild-type CGNPs infected with lentiviruses carrying short hairpin RNAs (shRNAs) targeting mouse E2F1 or a scrambled shRNA were evaluated. As shown in Figure 4d , uninfected or scrambled shRNA-infected Shh-treated CGNPs have elevated E2F1, cleaved SREBP1 and FASN, in conjunction with increased proliferation as indicated by Rb phosphorylation and cyclin D2 elevation. Importantly, Shh-treated CGNPs also showed marked reduction in the levels of MCAD, consistent with Shh ability to suppress FAO and downregulate MCAD mRNA expression as shown earlier (Figures 3b,  c and 4e ). In contrast, E2F1 knockdown reduced levels of E2F1, as expected, as well as reduced levels of proliferation markers like phosphorylated Rb and cyclin D2. Importantly, E2F1 knockdown markedly blunts both SREBP1 and FASN protein levels and notably rescues MCAD expression. Consistently, E2F1 knockdown also reverses Shh-mediated FAO suppression (Figure 4e ). This is also consistent with the effect seen earlier with inhibition of Shh signaling with cyclopamine in CGNPs (Figure 3) . Thus, genetic ablation of E2F1 and in vitro lentivirus-mediated E2F1 knockdown reveal a requirement for E2F1 in Shh-mediated CGNP proliferation and FASN expression, concomitant with Inhibition of E2F activity or FASN blocks Shh-associated medulloblastoma cell proliferation and viability in vitro The requirement for Shh-driven E2F1-mediated lipogenesis in CGNP proliferation suggests that targeting E2F1 activity and lipid synthesis pathways could be effective in blocking Shh-induced medulloblastoma growth. Pzp53med cells were used to test the effects of E2F1 and lipogenesis inhibition on tumor cells. These cells were derived from a mouse Ptc þ /À /p53 À/À medulloblastoma and they have been used to model Shh mitogenic signaling (Berman et al., 2002; Corcoran and Scott, 2006) . Treatment of Pzp53med cells with the cdk inhibitor roscovitine (10 nM) resulted in reduced levels of E2F1, FASN, Bmi1 (an E2F1 and Shh target (Leung et al., 2004; Nowak et al., 2006) ), cyclin D2, cdk2 and cdk4 (Figure 5a ). This is associated with a cessation of proliferation as determined by quantification of phospho-histone H3 staining. Next, we used C75, an inhibitor of FASN (Thupari et al., 2002; McCullough et al., 2005) , shown to block lung tumor growth in mice (Orita et al., 2007 (Orita et al., , 2008 . Treatment of these cells with C75, like roscovitine, significantly reduced proliferation (Figure 5b) . Moreover, western blot analysis reveals that while cdk inhibition, FASN inhibition and the combination, all result in reduced levels of the lipogenic enzyme FASN and proliferation markers, C75 potently induces cell death as suggested by increased levels of cleaved caspase 3 (Figure 5c ). This was confirmed by quantification of viability ( Figure 5d ); C75 synergized with increasing doses of roscovitine in driving Pzp53med cell death. Collectively, these findings indicate that, in these Shh-associated medulloblastoma cells where E2F1 is deregulated, FASN activity is required for both proliferation and survival. Hedgehog signals via E2F1 to promote lipogenesis B Bhatia et al
Cdk inhibition or counteracting lipogenesis reduces tumor growth and improves survival of Shh-driven medulloblastoma-bearing mice in vivo The sensitivity of Pzp53med cells to cdk inhibition suggests a therapeutic potential for cdk inhibition in Shh-associated medulloblastomas in vivo. We therefore carried out a 2-week treatment regimen of the cdk inhibitor olomoucine (intraperitoneal, 3 mg/kg daily) or vehicle control on NeuroD2-SmoA1-transgenic mice bearing medulloblastomas as determined by symptomology (slight head tilt, minimal seizure), and magnetic resonance imaging. A total of 10 mice were used for each treatment. Olomoucine was used instead of roscovitine as dose escalation and toxicity studies (data not shown) indicated better brain penetration by this drug. Olomoucine treatment markedly extended survival of mice with medulloblastomas ( Figure 6a ). Immunocytochemistry and western blotting revealed that olomoucine effectively reduced E2F1 levels, downmodulated cdk pathway activity, and impaired proliferation as indicated by reduced levels of PCNA, N-myc, and cyclin D2 (Figures 6b and c ). An increase in cleaved caspase 3 in tumors of treated mice reflects an increase in the apoptotic index. A marked reduction in FASN levels with olomoucine is also detected consistent with reduced levels of E2F1 in vivo, and with results shown in Figures 4 and 5. We asked whether counteracting FASN-mediated lipogenesis would be sufficient to influence tumor pathophysiology in vivo and affect survival of medulloblastoma-bearing mice. First, we examined the effect of a short-term treatment regimen with the FASN inhibitor C75 (intraperitoneal, 30 mg/kg) on lipid accumulation. Medulloblastomas from drug-treated animals have no detectable neutral lipid staining, in contrast to the striking accumulation of lipid droplets in tumor-bearing vehicle-treated mice as determined by Oil Red O staining (Figure 7a ). Western blot analysis of cerebella and medulloblastomas from vehicle or C75-treated mice also reveals reduced levels of FASN, consistent with abrogated de novo lipid synthesis as well as downmodulation of proliferation markers like cyclin D2, N-myc and cdk2 (Figure 7b ). Consistently, a marked reduction in mitosis as reflected by phospho-histone H3 quantification was observed in the tumors of C75-treated animals (Figure 7c ). Importantly, treatment of NeuroD2-SmoA1-tumor bearing mice with C75 promotes a remarkable increase in survival of these animals as compared with vehicle-treated tumor-bearing counterparts (Figure 7d) . Evidently, counteracting lipogenesis in Shh-driven medulloblastomas, like inhibition of cdks, reduces tumor growth and improves survival in vivo. Together, our findings establish a connection, in vivo and ex vivo, between Shh mitogenic signaling and the E2F1-FAS axis. This link underscores the coupling between Hh-dependent proliferation and the regulation of lipogenic machinery, deregulation of which as shown here is a prominent feature in medulloblastoma. 
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Discussion
Shh mitogenic signaling is critical in normal development and its aberrant activity is implicated in a wide range of human cancers like medulloblastoma, basal cell carcinoma, lung and pancreatic cancers to name a few. A better understanding of the mechanisms through which excessive Shh signaling engages the cell cycle machinery and recruits metabolic pathways to promote uncontrolled proliferation would characterize the oncogenic networks involved in the biology of cancer and as such inform therapeutic modalities. This will also improve our comprehension of Shh function in normal development and cell growth. Here, we show-using in vivo and ex vivo analyses-that Shh mitogenic/ oncogenic signaling is tightly coupled to the reprogramming of mitochondrial bioenergetics: Shh inhibits the process of FAO while driving increased FAS, an early critical step of lipogenesis to favor tumor growth. The effects of Shh on regulating this fundamental aspect of lipid metabolism are observed in CGNPs in vivo during development, as well as in primary cultures in vitro. Exaggerated de novo lipid synthesis and intracellular lipid accumulation with striking pathological features similar to those observed in the diabetic heart or with hepatic steatosis also mark Shh-dependent (NeuroD2-SmoA1) medulloblastomas. Importantly, Shh signaling engages the Rb/E2F1 tumor suppressor complex, inactivating Rb and inducing E2F1, a process we found essential for the effect of Shh on the lipogenic/ lipolytic balance. These findings provide new mechanistic insight into how the Rb/E2F1 complex contributes to Shh-dependent proliferation and medulloblastoma (Marino et al., 2000; Olson et al., 2007) , in that E2F1 has a pivotal role integrating the cell cycle regulatory machinery with metabolic pathways essential for cell growth, downstream of Shh. These novel connections between Shh signaling, E2F1 activation and mitochondrial reprogramming of cellular bioenergetics favoring lipogenesis have broad implications for the treatment of Shh-associated cancers: they present lipogenesis inhibitors as potentially effective pharmacological tools to counteract hyperproliferative signals in tumors, downstream of Shh signaling.
In proliferating CGNPs, Shh pathway activation stimulates expression of FASN and ACC in an E2F1-dependent manner, and suppresses FAO, concomitant with a marked reduction of FAO markers like MCAD and ACOX1. Similarly, high levels of E2F1 are expressed in conjunction with FASN in CGNPs occupying the EGL of the developing cerebellum during the peak of Shh-mediated CGNP proliferation. Moreover, loss of E2F1 blunts Shh-mediated proliferation and downregulates expression of lipogenic markers, including FASN. These findings contrast with a report that Shh inhibits adipogenesis in Drosophila fat bodies and 3T3-L1 cells (Suh et al., 2006) . In those studies, nonproliferating cells in which Shh signaling was activated showed reduced levels of lipid accumulation and reduced expression of adipogenic transcription Hedgehog signals via E2F1 to promote lipogenesis B Bhatia et al factors. To the contrary, we find that FASN is highly expressed in tumors with activated Shh signaling, consistent with the highly lipogenic phenotype apparent in the tumors as shown in Figures 1 and 7 . The effects of Shh signaling on lipogenesis could be highly nuanced and may depend on the proliferation competency of the Shh-responsive cells. Nonetheless, active lipogenesis marks Shh-driven medulloblastomas in vivo, a process that can also be reversed using lipogenisis inhibitors.
Altered metabolic patterns are a hallmark of cancer cells. Many tumors have elevated glucose uptake and hexokinase activity, a feature associated with poor prognosis and exploited in diagnostic imaging techniques like fluorodeoxyglucose-positron emission tomography (Jones and Thompson, 2009 ). Conversely, some positive regulators of proliferation are associated with reduced hexokinase activities and reduced glycolysis. For example, antisensemediated cyclin D1 down-modulation has been shown to upregulate glycolysis in vivo, by releasing hexokinase II from inhibition (Sakamaki et al., 2006) . This reflects the complexity of the network underlying cancer-associated metabolic patterns and underscores its heterogeneity. It is also established that many cancer cells rely heavily on glutaminolysis (DeBerardinis et al., 2007; Tong et al., 2009) , a process linked to the activity of the myc oncogene (Wise et al., 2008; Gao et al., 2009) . Tumor suppressors such as p53, PTEN and LKB1 also influence key regulators of cellular metabolism (Jones and Thompson, 2009) . Recently, Akt-dependent SREBP-mediated FASN regulation has also been linked to survival of glioma cells with activating EGF receptor mutations (Guo et al., 2009a, b) . We detected increased levels of SREPB1 precursor and cleaved protein in Shhtreated CGNPs, and loss of E2F1 in vivo and in vitro led to a reduction in SREPB1 levels. Whether SREPB1 is responsible for FASN induction in CGNPs remains to be seen; we note, however, that changes in Akt activity are not observed in Shh-stimulated CGNPs (Parathath et al., 2008) , and indeed, EGF receptor levels are inversely correlated with Gli levels in human medulloblastomas (Ferretti et al., 2006) , indicating that FASN expression may be induced in CGNPs and Shhassociated medulloblastomas through a novel, E2F1-regulated process.
E2F1 directly regulates genes involved in cell cycle regulation, nucleotide biosynthesis, DNA replication, as well as apoptotic targets including caspases and Apaf-1 (Helin et al., 1993; Lees et al., 1993; Zhu et al., 1995; Dynlacht et al., 1997; Abrahamowicz et al., 2001; Nahle et al., 2002; Ren et al., 2002) . E2F1 can also promote genomic instability and contributes to cancer progression (Hernando et al., 2004) , through induction of the mitotic regulator Mad2. Previously, we identified pyruvate dehydrogenase kinase 4, a key nutrient sensor and an inhibitor of pyruvate dehydrogenase, as a direct E2F1 target, establishing a crucial role for E2F1 in Hedgehog signals via E2F1 to promote lipogenesis B Bhatia et al metabolic regulation of glucose oxidation proper (Hsieh et al., 2008) . HIF1a was also linked to the induction of another pyruvate dehydrogenase kinase family member (pyruvate dehydrogenase kinase 1) and the inhibition of pyruvate dehydrogenase activity (Kim et al., 2006) . Herein, we demonstrate that the Rb/E2F1 axis acts downstream of Shh to control the expression of lipogenic enzymes, promote active lipogenesis, and fuel tumor growth in medulloblastoma. This further underscores the intimate link between excessive E2F1 activity and the priming of hyperproliferative metabolic patterns, during both normal development and in tumors. Shh-stimulated CGNPs and Shh-induced medulloblastomas exhibit high levels of FASN, a key lipogenic enzyme. This is functionally linked to high levels of neutral lipid accumulation, as evidenced by striking Oil Red O staining. Using both genetic and pharmacological approaches, we demonstrate a requirement for E2F1 in expression of FASN and for sustained suppression of FAO in both normally proliferating CGNPs and tumor cells. This connection between E2F1 and the lipogenic/ lipolytoic balance highlights a novel aspect of E2F1 function in cell cycle regulation and tumor cell growth, in addition to its well-established roles in regulating cell cycle progression and apoptosis genes, and highlights that E2F1-regulated metabolic pathways have important role in its oncogenic function. Further, direct inhibition of FASN by C75 resulted in medulloblastoma cell death in vitro and increased survival of medulloblastoma-bearing mice, associated with reduced lipid synthesis and decreased proliferation in the tumors in vivo. These data suggest a selective advantage for Shh-associated tumor cells with active lipogenesis, to which they become 'addicted'. The dependence of Shhassociated medulloblastomas on FAS may be exploited in therapeutic approaches aiming at counteracting de novo lipid synthesis downstream of Smo, and may reduce the side effects or surmount acquired resistance associated with targeting Smo itself (Kimura et al., 2008; Yauch et al., 2009) . Moreover, given that Hh pathway activation and Rb inactivation mark the majority of human malignancies; our work may have broad implications for therapies targeting the inextricable coupling between cell cycle control and lipogenesis, especially in cancers with Rb and/or Shh pathway defects. Finally, findings of this study are equally relevant to the pathophysiology of chronic diseases like obesity and diabetes, where lipid signaling and FAO are also dysregulated.
Materials and methods
Animal studies
All mouse work was carried out in compliance with the Weill Cornell Medical College and Memorial Sloan-Kettering Institutional animal care and use committee guidelines. Wild-type and NeuroD2-SmoA1 mice bearing tumors (kindly provided by Jim Olson of Fred Hutchinson Cancer Research Center, Seattle, WA, USA) were administered with 10% dimethyl sulfoxide (control), olomoucine at 3 mg/kg daily or C75 at 30 mg/kg through intraperitoneal injection. E2F1-null mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA).
Cell culture CGNP cultures were generated as previously described (Kenney et al., 2003) . Where indicated Shh (R&D Systems, Minneapolis, MN, USA) was used at a concentration of 3 mg/ml, cyclopamine (R&D Systems) was used at 10 mg/ml and C75 (Sigma, St Louis, MO, USA) was used at 10 mg/ml. Pzp53med cells, generously provided by Matt Scott (Stanford University, Stanford, CA, USA) were grown in Dulbecco 0 s modied Eagle 0 s medium/1% fetal calf serum, supplemented with antibiotics. As indicated, these cells were treated with roscovitine (Sigma; 10 nM for 18 h) or C75 compound.
Lentivirus production and infection. E2F1 shRNA and scrambled control lentivirus constructs were obtained from The RNAi Consortium library (Sigma). Each construct was transfected into Pzp53med cells, and western blotting was used to determine which shRNAs effectively and specifically targeted E2F1. These constructs were used to prepare lentiviruses. 293T cells, grown in 10% FBS Dulbecco 0 s modied Eagle 0 s medium medium, were transfected with E2F1 or scrambled control shRNA lentiviral vectors and MISSION lentiviral packaging mix (Sigma) using Fugene 6 in serum-free OPTI-MEM medium (Invitrogen, Carlsbad, CA, USA). Lentiviral supernatants were collected 48 h post-transfection and filtered through a 0.45 mm filter, then pooled. For infection, Shh-treated CGNPs were exposed to the lentiviral supernatent for 4 h. Control scrambled shRNA lentivirus constructs were used to determine specificity for E2F1 and to rule out off-target effects or non-specific results because of the process of virus infection. The lentiviruses were aspirated and replaced with serum-free CGNP medium (above) containing Shh. The cells were lysed or fixed 48 h post-infection.
Reverse transcription-PCR RNA was isolated using the TRIZOL reagent (Invitrogen) according to the manufacturer's protocol. RNA samples were resuspended in 35 ml diethylpyrocarbonate-treated water. Complementary DNA was generated with SuperScript FirstStrand Synthesis System for reverse transcription-PCR (Invitrogen) as per manufacturer's instructions. TaqMan Gene Expression Arrays (Applied Biosystems, Carlsbad, CA, USA) using TaqMan custom designed MGB probes for N-myc and cyclin D2 were performed in triplicate according to manufacturer's protocol on an ABI 7000 Sequence Detection System (Applied Biosystems). Data were analyzed with ABI GeneAmp SDS software (Applied Biosystems). The average threshold cycle (C T ) was determined to quantify transcript levels, normalized against b-actin and the results reported as fold changes. Cyber-green reverse transcription-PCR primers were used to detect E2F1 (5
, using a Biorad iCycler and companion software for analysis (Bio Rad, Hercules, CA, USA).
Western blotting
Protein extracts were prepared as previously described (Kenney and Rowitch, 2000) . A total of 40 mg murine cerebella and medulloblastoma protein, or 30 mg CGNP protein were run on 8-12% SDS-polyacrylamide gels and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). The blots were incubated with primary antibodies in 3% bovine serum albumin (in phosphate-buffered saline (PBS)-Tween) or 5% milk overnight in 4 1C. Blots were washed three times and incubated with secondary antibodies in 5% milk in Tris-buffered saline-Tween for 2 h in room temperature. After washing, the signals were developed using the enhanced chemiluminescence method (GE Healthcare, Piscataway, NJ, USA) and the membranes were exposed to Kodak Biomax film. Primary antibodies were: E2F1 (Cell Signaling, Danvers, MA, USA), FASN (Cell Signaling), MCAD (Abcam, Cambridge, MA, USA), Phospho-Rb S608 and S720 (Cell Signaling), total Rb (Cell Signaling), SREBP1 (Cell signaling), cdk2 (M-2; Santa Cruz, Santa Cruz, CA, USA), cdk4 (C-22; Santa Cruz), cdk6 (C-21; Santa Cruz), N-myc (C19, Santa Cruz), b-tubulin (Sigma) and cyclin D2 (M-20; Santa Cruz). Horseradish peroxidase-conjugated secondary antibodies were: goat anti-rabbit IgG (H þ L; Thermo Scientific, Rockford, IL, USA) and donkey anti-mouse IgG (H þ L; Jackson ImmunoResearch, West Grove, PA, USA).
Immunoprecipitation kinase assay
Protein lysates were prepared as described above. Kinase assays were carried out precisely as described (Sjostrom et al., 2005) , using 200 mg of lysate. Antibodies used were: anti-Erk (9102, Cell Signaling Technology) and anti-Cdk2 (Santa Cruz, sc-163). Kinase substrates were: 1 mg histone H1 (Roche Applied Science, Indianapolis, IN, USA), 5 mg MBP (Upstate Biotechnology, Billerica, MA, USA). Results shown are representative of experiments carried out in triplicate.
Immunostaining
CGNPs and Pzp53med cells were fixed in 4% para-formaldehyde for 10 min. Cells were then washed with 1 Â PBS and permeabilized in 1% TritonX-100 for 5 min. Cells were blocked in 5% goat serum in PBS-Tween (1 Â PBS and 0.1% TritonX-100) for 1 h in room temperature, washed once with 1 Â PBS, and then incubated with primary antibody in 2.5% goat serum (in PBS-Tween) overnight at 4 1C. They were washed three times with 1 Â PBS and incubated with secondary antibody for 2 h in room temperature, then washed and mounted in 4 0 -6-diamidino-2-phenylindole-containing mounting medium (Vector Labs, Burlingame, CA, USA).
Paraffin-embedded tissue slides were processed as previously described before incubation with primary antibodies (Bhatia et al., 2009) . Primary antibodies used were: E2F1 (H-137; Santa Cruz), ACC (Cell Signaling), FAS (Cell Signaling), P-Histone H3 (Cell Signaling), cleaved caspase 3 (Cell Signaling), PCNA (Calbiochem, Gibbstown, NJ, USA). Secondary fluorescent-tagged antibodies were: Alexa Fluor goat anti-rabbit 488/594 (Invitrogen) and Alexa Fluor goat anti-mouse 488/594 (Invitrogen).
Image capturing
Immunostaining performed on cultured cells or tissue sections was visualized using a Leica DM5000B microscope and images were captured with Leica FW400 software (Leica Microsystems, Bannockburn, IL, USA). For quantification of phospho-histone H3 immunostaining, TIFF images of four random fields were taken for each experimental group using the Â 10 objective. The percentage of phospho-histone-H3-positive cells over the total number of cells, as determined by 4 0 -6-diamidino-2-phenylindole staining, was calculated using Image Pro Plus software (Media Cybernetics, Bethesda, MD, USA).
Statistics
Statistical analysis of quantitative immunostaining was performed using one-way ANOVA followed by a two-tailed t-test for comparisons between groups. All results are given as mean ± s.e.m. All in vitro experiments were performed at least three times with separate litters to confirm reproducibility and consistency.
Oil Red O staining Oil Red O staining of NeuroD2-SmoA1 medulloblastoma frozen sections was performed by the histology core in the Department of Pathology and Laboratory Medicine in the Hospital for Special Surgery and by the microcytometry core facility at Memorial Sloan-Kettering Cancer Center according to established protocols.
FAO assay
Radiometric palmitate oxidation assays were carried out according to established methods (Djouadi et al., 2003) . A reaction mixture was prepared by adding 60 mCi of [9,10(n)-3H]-palmitic acid to 2 ml of 10 mM unlabeled palmitic acid in absolute ethanol. After complete evaporation of the solvent, the fatty acid was resuspended in 12 ml Dulbecco 0 s modied Eagle 0 s medium containing 3% fatty acid-free bovine serum albumin and incubated at 4 1C overnight. The reaction mixture was further diluted with Dulbecco 0 s modied Eagle 0 s medium to a final concentration of 100 mmol/l palmitic acid. Cells were plated in 12-well plates. After overnight incubation, the monolayer cultures, at 90-100% confluency, were washed with PBS before addition of 300 ml of the reaction mixture. The cultures were then incubated at 37 1C for 2 h. At the end of the incubation, the reaction mixture was removed and added to a solution of 10% trichloroacetic acid followed by centrifugation at 4000 g at 4 1C for 10 min. The supernatant is then neutralized with 6 M NaOH and transferred to ion exchange resin columns (DOWEX1 Â 2-400, Sigma) for separating 3
